Lameness Repair Company

PetVivo Expands IP Assets With EU Drug Delivery Patent Grant

News Release

 

 

PetVivo Expands IP Assets With EU Drug Delivery Patent Grant

MINNEAPOLIS, MN October 26, 2015 PetVivo Holdings, Inc. (OTCPINK:PETV) an emerging biomedical device company focused on the commercialization of innovative medical devices for pets or pet therapeutics is pleased to announce the issuance of European Patent 1691746. With this recent issuance by the European Patent Office, PetVivo’s intellectual property portfolio has grown to twenty patents, eight of which are United States Patents. The company has an additional seventeen patent applications pending in the United States and strategic foreign countries.

 

This recently issued European Patent “Mucoadhesive Drug Delivery Devices and Methods of Making and Using Thereof,” secures twenty-six patent claims, including three independent claims related to the localized and systemic delivery of pharmacologically active agents through all types of mucosal tissues for the treatment of diseases, infections, wounds, inflammation/pain and other afflictions. Mucosal drug delivery is generally noninvasive and the attachment of the mucosal drug delivery device protects the pharmacologically active agents from elimination at the drug absorption site, thereby increasing drug absorption and bioavailability.

 

“We now possess the intellectual property to protect our proprietary mucosal delivery products and their veterinary and human treatment applications,” commented PetVivo’s CTO, Dr. David B. Masters, “This degradable mucosal attachment technology provides greater residency time to improve therapeutic effectiveness for a broad range of products, including delivery of nutraceuticals, vitamins, oral care agents, and a wide range of pharmaceuticals. We are pleased to have patent protection for our transmucosal delivery system that will initially target the dental hygiene, pain and incontinence markets in the veterinary space.”

 

This mucoadhesive drug delivery patent protects a broad range of human and animal therapeutics representing many significant market opportunities. One of the technologies covered in this patent is the mucosal pharmaceutical delivery system, OraPatch™, which is a slowly degradable protein wafer-disc that strongly attaches to and assimilates with the oral cavities mucosal membrane. OraPatch provides a nearly undetectable and secure mucosal attachment for the controlled release period so its contents can circulate within the mouth longer as it degrades away to dissolved material. In addition, OraPatch can be fabricated for transmucosal delivery, eliminating gastrointestinal tract issues that can be caused by traditional oral pharmaceutical delivery, enhancing bioavailability and reducing the amount of pharmacologically active agent needed.

The United States Patent and Trademark Office has previously issued a corresponding patent number 8,529,939 titled “Mucoadhesive Drug Delivery Devices and Methods of Making and Using Thereof”. In addition, both the Canadian and Australian Patent Offices have also allowed a corresponding patent.

 

“We are pleased to see the ongoing expansion of the intellectual property related to our medical device and drug delivery device platforms. This expansion highlights the novelty of our many protein based materials and devices,” commented PetVivo CEO John Lai, “We continue to show that our protein particles improve the quality of life for dogs and horses suffering from osteoarthritis. We are seeing success beyond eighteen months after a single treatment of the Kush particles.”

 

To treat lameness a licensed veterinarian injects the Kush particles into the affected joints. Kush’s soft, resilient particles work by providing a protective cushion to the joint where its natural cartilage is missing or damaged. These particles are formulated to provide the mechanical support required to absorb the forces found in an articulating joint.

 

PetVivo’s research estimates that osteoarthritis and lameness currently impacts twenty million dogs and one million horses in the United States and Europe. The Kush devices are part of a portfolio of more than seventeen therapeutic candidates in various stages of development for both veterinary and human clinical applications.

 

The company diligently protects its proprietary technologies, including the composition of raw elements used to produce its formulations, the fabricated biomaterials and their application in end products and devices. To maximize the strength and value of PetVivo’s intellectual property the claims generally cover the commercial devices/therapeutics, the manufacturing methods and the methods of use of the company’s proprietary technology.

 

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

 

PetVivo’s strategy is to acquire or in-license proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for commercial launch later this year.

 

For more information, visit: www.PetVivo.com

 

Forward-Looking Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

Real Time Web Analytics